PharmaCielo (PCLO) Price & Analysis

Q: What was PharmaCielo’s price range in the past 12 months?

PharmaCielo lowest stock price was C$0.03 and its highest was C$0.17 in the past 12 months.

Q: What is PharmaCielo’s market cap?

PharmaCielo’s market cap is C$10.00M.

Q: When is PharmaCielo’s upcoming earnings report date?

PharmaCielo’s upcoming earnings report date is May 04, 2026 which is in 69 days.

Q: Is PharmaCielo overvalued?

According to Wall Street analysts PharmaCielo’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Q: Does PharmaCielo pay dividends?

PharmaCielo does not currently pay dividends.

Q: What is PharmaCielo’s EPS estimate?

PharmaCielo’s EPS estimate for its next earnings report is not yet available.

Q: How many shares outstanding does PharmaCielo have?

PharmaCielo has 187,893,690 shares outstanding.

Q: Which hedge fund is a major shareholder of PharmaCielo?

Currently, no hedge funds are holding shares in TSE:PCLO

Q: What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Compare

50 Followers

PCLO Stock Chart & Stats

C$0.04

<C$0.01(5.56%)

At close: Jan 08 4:00 PM EST

C$0.04

<C$0.01(5.56%)

Day’s Range― - ―

52-Week RangeC$0.03 - C$0.17

Previous CloseN/A

Volume2.00K

Average Volume (3M)0.00

Market Cap

C$10.00M

Enterprise ValueC$26.96M

Total Cash (Recent Filing)C$256.57K

Total Debt (Recent Filing)C$17.82M

Price to Earnings (P/E)―

Beta-1.79

Next Earnings

May 04, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding187,893,690

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio0.02

Price to Book (P/B)-1.87

Price to Sales (P/S)4.03

P/FCF Ratio-7.12

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Medical/pharma FocusA dedicated medical and pharmaceutical-cannabinoid focus positions the company in higher-barrier, regulated end markets. Structural demand for compliant cannabinoid inputs and specialized processing can support durable commercial relationships and pricing stability versus commodity recreational segments.

Return To Positive Gross ProfitRestoring positive gross profit indicates the core cultivation and processing economics can cover direct production costs. If sustained, this improvement provides a foundation to absorb SG&A and move toward operating profitability as volumes and operational efficiency scale.

Reduced Cash BurnA materially smaller operating cash outflow versus prior years extends runway and lowers near-term financing pressure. Continued reduction in cash burn is a durable indicator of improving operational control and increases the chance of reaching self-funded operations absent adverse shocks.

Bears Say

Negative Equity / Weak Balance SheetNegative equity reflects accumulated losses and a fragile capital base. High debt relative to small assets elevates insolvency and refinancing risk, constrains strategic flexibility, and raises the cost or scarcity of additional capital until equity is rebuilt or debt materially reduced.

Persistent Negative Cash FlowSustained negative operating and free cash flow forces ongoing external financing, increasing dilution or leverage. This structural cash shortfall limits capacity to invest in growth, maintain facilities, or weather regulatory and market volatility without securing fresh capital.

Declining Revenue And Deep LossesA meaningful revenue decline combined with extreme negative net margins signals the core business remains unprofitable at scale. Without persistent revenue recovery or significant cost restructuring, operating losses will continue to erode liquidity and shareholder value.

PharmaCielo News

PharmaCielo Sets AGM Date and Moves to Pay Debenture Interest in Shares

An update from PharmaCielo ( ($TSE:PCLO) ) is now available. PharmaCielo Ltd. has scheduled its annual general meeting...

7d ago

PharmaCielo Shares to Resume Trading as Cease Trade Order Lifted and Insider Financing Detailed

PharmaCielo ( ($TSE:PCLO) ) has provided an update. PharmaCielo has had its failure-to-file cease trade order revoked by...

2M ago

PharmaCielo Faces Cease Trade Order Amid Financial Filing Delay

PharmaCielo ( ($TSE:PCLO) ) has issued an update. PharmaCielo Ltd. announced that the Ontario Securities Commission has issued...

7M ago

PharmaCielo Achieves Remarkable Sales Growth and Financial Stability in Q4 2024

PharmaCielo ( ($TSE:PCLO) ) has issued an announcement. PharmaCielo reported a significant financial turnaround in Q4 2024, achieving...

12M ago

PharmaCielo Issues Shares to Settle Debts and Interest

PharmaCielo ( ($TSE:PCLO) ) has issued an update. PharmaCielo announced its plans to issue shares to settle certain...

1y ago

PharmaCielo’s Revenue Soars with Strategic Growth

PharmaCielo (TSE:PCLO) has released an update. PharmaCielo reported an impressive 85% year-over-year sales growth, achieving a total revenue...

1y ago

PharmaCielo Extends Warrant Expiry to Boost Market Position

PharmaCielo (TSE:PCLO) has released an update. PharmaCielo Ltd. has announced its plan to extend the expiry date of...

1y ago

PharmaCielo Shifts Fiscal Year-End and Names New Auditor

PharmaCielo (TSE:PCLO) has released an update. PharmaCielo, a Canadian-based global medical cannabis company, has announced a change in...

1y ago

PharmaCielo’s Financial Health Improves in Q2 2024

PharmaCielo (TSE:PCLO) has released an update. PharmaCielo has reported an improvement in its financial results for Q2 2024,...

2y ago

PharmaCielo Nears Trading Reinstatement and Secures Funding

PharmaCielo (TSE:PCLO) has released an update. PharmaCielo, a leader in medicinal-grade cannabis cultivation and production, has announced that...

2y ago

PCLO FAQ

What was PharmaCielo’s price range in the past 12 months?

PharmaCielo lowest stock price was C$0.03 and its highest was C$0.17 in the past 12 months.

What is PharmaCielo’s market cap?

PharmaCielo’s market cap is C$10.00M.

When is PharmaCielo’s upcoming earnings report date?

PharmaCielo’s upcoming earnings report date is May 04, 2026 which is in 69 days.

How were PharmaCielo’s earnings last quarter?

Currently, no data Available

Is PharmaCielo overvalued?

According to Wall Street analysts PharmaCielo’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does PharmaCielo pay dividends?

PharmaCielo does not currently pay dividends.

What is PharmaCielo’s EPS estimate?

PharmaCielo’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does PharmaCielo have?

PharmaCielo has 187,893,690 shares outstanding.

What happened to PharmaCielo’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of PharmaCielo?

Currently, no hedge funds are holding shares in TSE:PCLO

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

PharmaCielo

PharmaCielo Ltd., together with its subsidiary, cultivates, processes, produces, and supplies medicinal-grade cannabis extracts, tetrahydrocannabinol, and related products. The company also offers telemedicine software. It serves health and wellness product manufacturers, pharmacies, medical clinics, and cosmetic companies in Canada and Colombia. The company has a strategic alliance with AssuredTrans Inc. PharmaCielo Ltd. is headquartered in Toronto, Canada.